Individualized Cancer Treatment MRNA Vaccine is the fastest-growing line in the global mrna vaccines and therapeutics market, compounding at 17.52% through the forecast period and pulling revenue share away from infectious-disease prevention products. Its share of market revenue climbs from 9% in 2025 to 15% in 2034, and its value rises from USD 1.16 billion to USD 5.13 billion.
The market as a whole was valued at USD 12.85 billion in 2025. Contrive Datum Insights projects USD 14.58 billion in 2026 and USD 34.19 billion by 2034, a compound annual growth rate of 11.24%. The findings come from the report "Mrna Vaccines And Therapeutics Market Size, Share & Industry Analysis, By Type, Application, Treatment type, Technology, Delivery system, and Regional Forecast, 2026-2034".
The market covers products that use synthetic messenger RNA to instruct a patient's own cells to produce a target protein. The aim is an immune response against a pathogen or tumor antigen, or the supply of an antibody, gene or cell-therapy function. Buyers include national immunization programs, hospital and specialty oncology networks, and biopharmaceutical developers licensing the delivery platform.
Why Individualized Cancer Vaccines Are Pulling Ahead
Progress in the oncology pipeline toward approved mRNA cancer vaccines is the largest single contributor to growth over the forecast period, and the study rates its impact high. Individualized products are the type line most exposed to it, which explains a growth rate well above the market's 11.24%.
The outcome depends on how quickly candidates reach approval. The bull case assumes faster approval of therapeutic cancer and non-COVID infectious-disease candidates, steady investment in manufacturing capacity and no major delivery-platform safety setback. Under those terms, 2034 revenue reaches USD 43.26 billion. The bear case assumes slower trial-to-approval progress, tighter reimbursement after pandemic-era emergency funding winds down, and manufacturing capacity that grows more slowly than planned. That path holds 2034 revenue to USD 25.67 billion.
Other segments show the same pattern of small lines growing quickly. Circular and Other Next-Generation mRNA grows at 20.41% within the technology axis, Cell Therapy at 14.5% by treatment type, Peptide-Based delivery at 17.54%, and Clinic at 12.97% by application.
Regionally, North America leads with 46% of 2025 revenue, or USD 5.92 billion, rising to USD 14.36 billion in 2034. The United States alone accounts for USD 5.33 billion, or 41.48% of global revenue. Asia Pacific gains share, moving from 19% in 2025 to 24% in 2034 as revenue grows from USD 2.44 billion to USD 8.21 billion. Middle East and Africa holds at 4% in both years.
The Largest Segment Grows Slowest
Infection Prevention MRNA Vaccine remains the biggest type line, with 52% of 2025 revenue and USD 6.68 billion. It is forecast to hold 32% in 2034. Growth of just 5.26% a year sits far below the market average, so the segment that anchors today's revenue contributes the least to its expansion.
Among the other axes, Hospital leads by application at 58% of revenue, Monoclonal Antibody leads by treatment type at 35%, Conventional mRNA leads by technology at 78%, and Lipid Nanoparticle (LNP)-Based systems lead delivery at 84%.
The report covers five segmentation axes with revenue and growth rates for every line from 2020 to 2034, bear, base and bull scenarios, all five regions with country-level detail, the competitive landscape and the research methodology. It is delivered as a PDF, and a free sample is available on request.